Denny F.Acute respiratory infections in children: etiology and epidemiology . Pediatr Rev.1987;9:135-146.
2.
Anderson LJ, Hendry RM, Pierik L., et al. Multicenter study of strains of respiratory syncytial virus . J Infect Dis.1991;163:687-692.
3.
Heilman CARespiratory syncytial and parainfluenza viruses. J Infect Dis.1990;161:402-406.
4.
Agius G., Dindinaud R., Biggar J., et al. An epidemic of respiratory syncytial virus in elderly people: clinical and serological findings. J Med Virol.1990;30:117-127.
5.
Ribavirin and respiratory syncytial virus. Lancet.1986;1:362-363. Editorial.
6.
Anderson LJ, Parker RA, Strikas RLAssociation between respiratory syncytial virus outbreaks and lower respiratory tract deaths of infants and young children. J Infect Dis.1990;161:640-646.
7.
Hall CB, Walsh EE, Long CE, Schnabel KCImmunity to and frequency of reinfection with respiratory syncytial virus . J InfectDis.1991:163:693-698.
8.
Welliver RC, Sun M., Rinaldo D., Ogra PLPredictive value of respiratory syncytial virus-specific IgE responses for recurrent wheezing following bronchiolitis. J Pediatr.1986;109:776-780.
9.
McMillan JA, Tristram DA, Weiner LB, et al. Prediction of the duration of hospitalization in patients with respiratory syncytial virus infection: use of clinical parameters. Pediatrics. 1988;81:22-26.
10.
Groothuis JR , Salbenblatt CK, Lauer BASevere respiratory syncytial virus infection in older children. Am J Dis Child.1990;144:346-348.
11.
Abman SH, Ogle JW, Butler-Simon N., et al. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr.1988;113:826-830.
12.
Chandwani S. , Borkowsky W., Krasinski K., et al. Respiratory syncytial virus infection in human immunodeficiency virus-infected children . J Pediatr.1990;117:251-254.
13.
Hertz MI, Englund JA, Snover D., et al. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature. Medicine. 1989;68:269-281.
14.
Ahluwalia G. , Embree J., McNicol P., et al. Comparison of nasopharyngeal aspirate and nasopharyngeal swab specimens for respiratory syncytial virus diagnosis by cell culture, indirect immunofluorescence assay, and enzyme-linked immunosorbent assay. J Clin Microb. 1987;25:763-767.
15.
Waner JL, Whitehurst NJ, Todd SJ, et al. Comparison of directigen RSV with viral isolation and direct immunofluorescence for the identification of respiratory syncytial virus. J Clin Microbiol.1990;28:480-483.
16.
Hall CBHospital-acquired pneumonia in children: the role of respiratory viruses . Semin Respir Infect. 1987;2:48-56.
17.
Agah R., Cherry JD, Garakian AJ, Chapin M.Respiratory syncytial virus (RSV) infection rate in personnel caring for children with RSV infections. Am J Dis Child.1987;141:695-697.
18.
Leclair JM, Freeman J., Sullivan BF, et al. Prevention of nosocomial respiratory syncytial virus infections through compliance with glove and gown isolation precautions. N Engl J Med.1987 ;317:329-334.
19.
Krasinski K. , LaCouture R., Holzman RS, et al. Screening for respiratory syncytial virus and assignment to a cohort at admission to reduce nosocomial transmission . J Pediatr.1990;116:894-898.
20.
Timmons OD, Yamauchi T., Collins SR, et al. Association of respiratory syncytial virus and Streptococcus pneumoniae infection in young infants. Pediatr Infect Dis J.1987;6:1134-1135.
21.
Nederhand KC , Solon J., Sweet JI, Conner SCRespiratory syncytial virus: a nursing perspective . Pediatr Nursing. 1989;15:342-345.
22.
Hall CB, McBride JTVapors, viruses and views: ribavirin and respiratory syncytial virus . Am J Dis Child.1986;140:331-332.
23.
Snell NJEconomic and long-term benefits of ribavirin therapy on respiratory syncytial virus infection. Lung.1990;168:S422-S429.
24.
Hall CB, McBride JT, Walsh EE, et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. N Engl J Med.1983 ;308:1443-1447.
25.
Taber LH, Knight V., Gilbert BE, et al. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics . 1983;72:613-618.
26.
Conrad DA, Christenson JC, Waner JL, Marks MIAerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic. Pediatr Infect Dis J.1987;6: 152-158.
27.
Groothuis JR, Woodin KA, Katz R., et al. Early ribavirin treatment of respiratory syncytial viral infection in high-risk children. JPediatr. 1990;117:792-798.
28.
Browne MJComparative inhibition of influenza and parainfluenza virus replication by ribavirin in MDCK cells. Antimicrob Agents Chemother.1981;19:712-715.
29.
McClung HW, Knight V., Gilbert BE, et al. Ribavirin aerosol treatment of influenza B virus infection. JAMA.1983;249:2671-2674.
30.
Wilson SZ, Gilbert BE, Quarles JM, et al. Treatment of influenza A (H1N1) virus infection with ribavirin aerosol. Antimicrob Agents Chenwther.1984 ;26:200-203.
31.
Stein DS, Creticos CM, Jackson GG, et al. Oral ribavirin treatment of influenza A and B. Antimicrob Agents Chemother.1987 ;31:1285-1287.
32.
Ferrara EA, Oishi JS, Wannemacher RW Jr, Stephen ELPlasma disappearance, urine excretion, and tissue distribution of ribavirin in rats and rhesus monkeys. Antimicrob Agents Chemother.1981;19:1042-1049.
33.
Englund JA, Piedra PA, Jefferson LS, et al. High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. J Pediatr.1990;117:313-320.
34.
Frankel LR, Wilson CW, Demers RR, et al. A technique for the administration of ribavirin to mechanically ventilated infants with severe respiratory syncytial virus infection. Crit Care Med.1987;15:1051-1054.
35.
Smith DL, Frankel LR, Mathers LH, et al. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med.1991;325:24-29.
36.
Hemming VG, Rodriguez W., Kim HW, et al. Intravenous immunoglobulin treatment of respiratory syncytial virus infections in infants and young children. Antimicrob Agents Chemother.1987;31:1882-1886.
37.
Gruber WC, Wilson SZ, Throop BJ, Wyde PRImmunoglobulin administration and ribavirin therapy: efficacy in respiratory syncytial virus infection of the cotton rat. PediatrRes.1987;21:270-274.
38.
Rosner IK, Welliver RC, Edelson PH, et al. Effect of ribavirin therapy on respiratory syncytial virus-specific IgE and IgA responses after infection. J Infect Dis.1987;155:1043-1047.
39.
Report of the Committee on Infectious Diseases. 22nd ed. Elk Grove Village, IL: American Academy of Pediatrics; 1991.
40.
Gelfand EWRibavirin treatment of viral pneumonitis in severe combined immunodeficiency disease. Lancet. 1983;2:732-733.
41.
McIntosh K. , Kuracheck SC, Cairns LM, et al. Treatment of respiratory viral infection in an immunodeficient infant with ribavirin aerosol . Am J Dis Child.1984;138:305-308.
42.
Kochhar DM, Penner JD, Knudsen TBEmbryotoxic, teratogenic, and metabolic effects of ribavirin in mice . Toxicol Appl Pharmacol.1980;52:99-112.
43.
Rodriguez WJ , Kim HW, Brandt CD, et al. Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease. Pediatr Infect Dis J.1987;6:159-163.
44.
Janai HK, Marks MI, Zaleska M., Stutman HRRibavirin: adverse drug reactions, 1986 to 1988. Pediatr Infect Dis J.1990;9:209-211.
45.
Kawana F., et al. Inhibitory effects of antiviral compounds on respiratory syncytial virus replication in vitro. Antimicrob Agents Chemother.1987 ;31:1225-1230.
46.
Wyde PR, Ambrose MW, Meyer HL, et al. Evaluation of the toxicity and antiviral activity of carbocyclic 3-deazaadenosine against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats. Antiviral Res.1990;14:215-226.
47.
Groothuis JR , Levin MJ, Rodriguez W., et al. Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. Antimicrob Agents Chemother.1991;35:1469-1473.
48.
Murphy BR, Sotnikov A., Paradiso PR, et al. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine.1989;7:533-540.
